RPS6KB1 and neoplasm: To develop combination targeting of S6K1 and AXL in a PTEN-deficient patient-derived low-passage glioblastoma model, we investigated the effects of treatment with the S6K1 inhibitor LY-2584702 in combination with the AXL inhibitor BMS-777607 in gliomaspheres, which can better preserve GBM tumor-propagating cellular states (47, 48).